The Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. The S & P 500 and Nasdaq rose Tuesday, led by a rebound in Club holding Nvidia . The chipmaker gained more than 3% as it looked to break three straight sessions of declines, including Monday's 6% plunge, its biggest single-day drop since April 19. Jim Cramer argued that the market's been too focused on the AI darling.
In May, DuPont announced plans to spinoff into three publicly-traded companies — a move the Club has described as a win for shareholders. Shares of the materials giant edged lower on Tuesday. Eli Lilly stock jumped 2% Tuesday after peer Novo Nordisk's Wegovy was approved for long-term weight management in China. Eli Lilly stock jumped 2% Tuesday after peer Novo Nordisk's Wegovy was approved for long-term weight management in China.
Morning Meeting Recaps Jim Cramer Investment Strategy Markets Breaking News: Markets S&P 500 Index NASDAQ Composite NVIDIA Corp Dupont De Nemours Inc Xylem Inc Veralto Corp Eli Lilly And Co Novo Nordisk A/S Metals And Minerals Industry Stock Markets Breaking News: Technology Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rollingEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »